Skip to content

As Terbinafine Resistance Incidents Rise, New Reflex Detects Mutations

As Terbinafine Resistance Incidents Rise, New Reflex Detects Mutations

By BakoDx

While onychomycosis caused by dermatophytic fungi are most often treated with terbinafine, an increasing incidence of cases with terbinafine resistance mutations may be impeding treatment success.

terbinafine

A new terbinafine resistance assay, available only with the BakoDx Onychodystrophy PCR Test, can quickly detect these resistance-associated mutations, so prescribing physicians can limit ineffective medications and increase treatment efficacy. BakoDx, a diagnostic leader in dermatopathology and molecular analysis (PCR), has developed a real-time PCR assay that detects these 12 fungal mutations, and identifies terbinafine resistance in Trichophyton rubrum and Trichophyton mentagrophytes

Dermatophytic fungi, primarily T. rubrum and T. mentagrophytes, are the leading cause of mycotic nail infections. However, there is a global public health concern that the most common antifungal treatment, terbinafine, may become less effective due to genetic mutations found in members of the Trichophyton genera, which have been shown to confer resistance to this agent.

This newly developed assay is offered as a reflex test, meaning that only specimens confirmed as T. rubrum or T. mentagrophytes by the BakoDx proprietary onychodystrophy assay will be screened for the mutations associated with terbinafine resistance.

“As all physicians involved in the treatment of patients with onychomycosis know all too well, the therapeutic difficulties and patient frustrations encountered with managing this problem are real,” said Dr. Wayne L. Bakotic, Chief Medical Officer and co-founder of BakoDx. “The emergence of terbinafine resistance has complicated the issue all the more.”

Read the complete article here: https://bit.ly/3GGJbDv.

UPCOMING EVENTS

CPMA SPOTLIGHT

President’s Message • Winter 2024

January 30, 2024

President’s Message From the desk of Kristen Winters CPMA is hitting the ground running in 2024, and we’re happy to have so many dedicated members along on this journey with…

Meet CPMA Board Member Dr. Danielle Butto!

January 26, 2024

Envisioning our Future with Dr. Danielle Butto For over 100 years the Connecticut Podiatric Medical Association has been devoted to serving members the best experiences and opportunities in the state.…

Scroll To Top